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Histone deacetylase inhibitors promote glioma cell
death by G2 checkpoint abrogation leading to mitotic
catastrophe
M Cornago1, C Garcia-Alberich1, N Blasco-Angulo1, N Vall-llaura1, M Nager2, J Herreros2, JX Comella3, D Sanchis1 and M Llovera*,1
Glioblastoma multiforme is resistant to conventional anti-tumoral treatments due to its infiltrative nature and capability of relapse;
therefore, research efforts focus on characterizing gliomagenesis and identifying molecular targets useful on therapy.
New therapeutic strategies are being tested in patients, such as Histone deacetylase inhibitors (HDACi) either alone or in
combination with other therapies. Here two HDACi included in clinical trials have been tested, suberanilohydroxamic acid (SAHA)
and valproic acid (VPA), to characterize their effects on glioma cell growth in vitro and to determine the molecular changes that
promote cancer cell death. We found that both HDACi reduce glioma cell viability, proliferation and clonogenicity. They have
multiple effects, such as inducing the production of reactive oxygen species (ROS) and activating the mitochondrial apoptotic
pathway, nevertheless cell death is not prevented by the pan-caspase inhibitor Q-VD-OPh. Importantly, we found that HDACi alter
cell cycle progression by decreasing the expression of G2 checkpoint kinases Wee1 and checkpoint kinase 1 (Chk1). In addition,
HDACi reduce the expression of proteins involved in DNA repair (Rad51), mitotic spindle formation (TPX2) and chromosome
segregation (Survivin) in glioma cells and in human glioblastoma multiforme primary cultures. Therefore, HDACi treatment causes
glioma cell entry into mitosis before DNA damage could be repaired and to the formation of an aberrant mitotic spindle that results
in glioma cell death through mitotic catastrophe-induced apoptosis.
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Glioblastoma multiforme (GBM) is an incurable cancer due to
its aggressiveness and its resistance to conventional anti-
tumoral therapies. Multiple genetic alterations are involved in
gliomagenesis leading to an aberrant activation of key
pathways involved in mitogenic signaling and cell cycle
control.1,2 The intratumoral heterogeneity combined with a
putative cancer stem cell subpopulation underlies the difficulty
to treat this cancer. The median survival of GBM patients
treated with multimodal therapies including surgical resection,
radiation and chemotherapy is less than 16 months due to
tumor relapse after surgical removal.3
Histone deacetylases (HDAC) are key regulators of cell
development and cancer, by deacetylating histones and other
proteins.4 Recent studies found that class I HDAC expression
was high in locally advanced, dedifferentiated and strongly
proliferating tumors, sometimes associated with compromised
patient prognosis.5 In contrast, a reduction in class II HDAC
expression was described in different types of tumors,
including GBM samples.6 Nevertheless, HDAC inhibitors
cause the acetylation of both histone and non-histone proteins
and exert multiple anti-tumoral effects by inducing differentia-
tion, apoptosis, cell cycle arrest, susceptibility to chemo-
therapy and inhibition of migration and angiogenesis.7
Therefore, HDACi are widely investigated and tested as
anticancer drugs. Initial clinical trials indicate that HDAC
inhibitors from several structural classes are well tolerated and
exhibit therapeutic activity against a variety of human
malignancies, and the pleiotropic molecular mechanisms of
action of these drugs are being uncovered.8–10 The elucidation
of the key molecular targets of HDACi involved in glioma cell
death is relevant for the development of more specific
therapeutic strategies.
Here, we characterize the response of glioma cell lines and
primary GBM cultures to two broad range HDACi being tested
in clinical trials against GBM: suberanilohydroxamic acid
(SAHA, vorinostat) and valproic acid (VPA). Both drugs are
able to kill glioma cells more efficiently than the chemo-
therapeutic drug temozolomide (TMZ). We also present the
analysis of the molecular alterations associated with glioma
cell death, showing that HDACi drive cells to mitotic
catastrophe and cell death by apoptosis.
Results
SAHA and VPA affect glioma cell viability, proliferation
and clonogenicity. On WST-1 assays, SAHA and VPA
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decreased cell viability in a concentration-dependent manner
(Figure 1a). Only at intermediate concentrations, differences
between glioma cell lines were observed, being U251-MG cells
less sensitive than U87-MG cells. LC50 values (Figure 1a)
showed that U251-MG has the lower sensitivity to both HDACi.
Similar results were obtained by viable cell counting using
trypan blue exclusion at selected HDACi concentrations
(Figure 1b), being 10 μMSAHAmore effective than 10mM VPA.
Next, we analyzed the effect of VPA and SAHA on cell
proliferation by Ki-67 immunodetection. Treatment with 10 μM
SAHA for 24 h reduced the percentage of proliferating cells
from a range of 70–90% to less than 20% in all cell lines
(Figure 1c), whereas 10mMVPA had a weaker effect and only
significant in U251-MG and LN229 cells. Clonogenic assays
showed that HDACi reduced significantly the capability of cells
to grow clonally after a 48-h treatment, (Figure 1d).
HDACi promote nuclear condensation and the activation
of the mitochondrial apoptotic pathway. Our results
showed that SAHA and VPA decrease cell viability dose
dependently. Therefore, to assess the participation of the
apoptotic cell death pathway on this effect, we analyzed the
Figure 1 SAHA and VPA reduce glioma cell viability, proliferation and clonogenicity. (a) Dose− response of glioma cell lines U87-MG, U373-MG and LN229 to VPA (upper
graph) and SAHA (lower graph) treatment by WST1- cell viability assay. Cells were treated for 48 h with increasing concentrations of HDACi. The LC50 for each cell line was
estimated by interpolation in the line-graph. Data shown are mean± S.E.M. from five independent experiments. Statistical comparisons were performed against the most
sensitive cell line, U87-MG. (b) Cell viability of glioma cell lines after 48- h treatment with 10 mM VPA, 10 μM SAHA or left untreated. Cells were counted in a hemocytometer by
trypan blue exclusion. Data are mean±S.E.M. from five independent experiments. (c) Analysis of cell proliferation by Ki-67-positive nuclei counting after 48 h of HDACi treatment
(10 mM VPA or 10 μM SAHA). Data in the graphic are expressed as mean±S.E.M. of four independent experiments. (d) Clonogenic assay of glioma cell lines after 48-h
treatment with HDACi (see Materials and Methods for details). Representative images of the stained clones are shown on the left. Bar graph shows results obtained from four
independent experiments (Mean± S.E.M.). Statistical analysis were performed by the Student's T-test being *Po0.05; **Po0.01; ***Po0.001
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nuclear morphology of glioma cells after 24 h of treatment. As
a reference, apoptosis inducer TRAIL was added to cells at
100 ng/ml. Nuclear staining with Hoechst showed that HDACi
cause nuclear condensation and abnormal nuclear morphol-
ogy in some cells (Figure 2a). However, nuclear fragmenta-
tion was absent and it was very infrequent in TRAIL-treated
cells. Therefore, glioma cells do not show a typical apoptotic
nuclear fragmentation after VPA and SAHA treatment. In
addition, HDACi induced an increase in nuclear size in U87-
MG and LN229 cells, indicating that chromatin was remo-
deled due to histone acetylation (Supplementary Figure 1).
To determine whether HDACi induced the intrinsic apoptotic
pathway, we checked the expression and cleavage of caspase
9 and caspase 3 by western blot (Figure 2b) and executioner
caspase activity by a fluorogenic assay (Figure 2c).
We observed that 10 μM SAHA promoted the cleavage of
both Caspase 9 and Caspase 3, whereas 10mM VPA had a
weaker effect in all glioma cell lines. As expected, Caspase-3
cleavage correlated with an increase in the DEVDase activity
of SAHA-treated cells (Figure 2c). Therefore, HDACi, mainly
SAHA at the concentration tested, are able to promote the
activation of the mitochondrial apoptotic pathway in glioma
cells. HDACi used in this study did not activate the extrinsic
apoptosis pathway on glioma cells (unpublished results).
HDACi promote DNA fragmentation in glioma cells,
which is dependent on the activation of the caspase/
CAD pathway. Next, we checked whether the activation of
Figure 2 VPA and SAHA induce nuclear condensation and caspase activation in glioma cell lines. (a) Nuclear morphology of U87-MG, U373-MG and LN229 after 24-h
treatment with 10 mM VPA, 10 μM SAHA or 100 ng/ml TRAIL. After treatment, cells were fixed in 4% PFA and nuclei were stained with Hoechst 33342. Condensed and abnormal
nuclei are indicated with yellow arrowheads. Scale bar= 50 μm. (b) Analysis of caspase-9, caspase-3 and fodrin expression and cleavage on glioma cell lines after 24-h
treatment with 10 mM VPA and 10 μM SAHA by western blot. Membrane was reprobed with an anti-α-tubulin antibody to verify equal loading. A representative blot from three
independent experiments is shown. (c) Caspase-3 activity in HDACi-treated cells. Glioma cells were treated with 10 mM VPA, 10 μM SAHA alone or in combination with the
caspase inhibitor Q-VD-OPh (5 μM) for 24 h. Cell lysates were incubated with Ac-DEVD-AFC fluorogenic substrate up to 8 h, and its cleavage was measured hourly using a
fluorometer. Bars depict mean± S.E.M. from four independent experiments. Statistical analysis was performed using the Student's T-test by comparing treated versus non-
treated (NT) cells (*Po0.05, **Po 0.01)
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the caspase cascade by HDACi promoted DNA fragmenta-
tion. We analyzed DNA integrity by Pulsed-field gel
electrophoresis (PFGE) and agarose gel electrophoresis
(Figure 3a). SAHA treatment for 48 h caused the formation
of 50- kb DNA fragments and the final DNA degradation in a
smear pattern (Figure 3a). Interestingly, the addition of a pan-
caspase inhibitor (Q-VD-OPh) blocked both high- and low-
molecular weight DNA fragmentation, indicating that caspase
activation was necessary for DNA degradation. Staurospor-
ine (STS), an apoptosis inducer, was added for 24 h to U251-
MG cells as a positive control for DNA fragmentation. The
formation of 50- Kbp DNA fragments was observed, but
typical oligonucleosomal laddering was not detected
(Figure 3a). These results indicated that U251-MG cells
exposed to an apoptosis inducer do not perform DNA
internucleosomal fragmentation. To further corroborate the
implication of the mitochondrial apoptotic pathway in SAHA-
induced DNA degradation, we overexpressed the antiapop-
totic gene BCL-X in U251-MG glioma cells (Figure 3b). We
observed that Bcl-xL-overexpressing cells were protected
against the induction of DNA degradation by SAHA, further
suggesting the involvement of the intrinsic apoptotic pathway
in SAHA effects.
One of the nucleases responsible for DNA processing on
caspase activation is Caspase-associated DNAse (CAD).11
Therefore, we next verified whether CAD endonuclease was
implicated in SAHA effects by using two shRNAs against CAD
mRNA that efficiently downregulate CAD protein levels in
U251-MG cells (Figure 3d). After SAHA treatment, we
observed that CAD downregulation blocked the formation of
50-Kbp and low-molecular weight DNA fragments, leading to
bigger DNA fragments showing a smear pattern on the upper
part of the gel. This indicates that CAD is the nuclease
implicated in the formation of 50-Kbp fragments on HDACi
treatment and suggests that 50-Kbp DNA processing is
required for the final low-molecular weight DNA degradation.
As suggested by the smear pattern that appears in PFGE
experiments when CAD expression is reduced (Figure 3c) but
not when caspases are inhibited with Q-VD-OPh (Figure 3a)
or on Bcl-xL overexpression (Figure 3b), other caspase-
activated nucleases may participate in DNA initial processing;
however, the identity of this nuclease/s remains to be
investigated.
As caspases were involved in DNA fragmentation, we next
checked the relevance of caspase activation in HDACi-
induced glioma cell death (Figure 3e). Trypan blue exclusion
cell counts showed that caspase inhibition did not prevent cell
death, indicating that cells died even in the absence of
caspase activation, thus indicating that the apoptotic pathway
is not required for HDACi-induced glioma cell death.
HDAC inhibition in glioma cells promotes DNA damage
partly due to ROS production. One of the mechanisms
involved in the activation of the mitochondrial pathway is the
activation of the DNA damage response. Therefore, we next
verified whether SAHA and VPA were able to promote the
formation of DNA double-strand breaks (DSBs). Cells treated
with temozolomide (TMZ), an alkylating drug in current use
for GBM treatment, were used as positive control (Figure 4a).
SAHA and VPA promoted an increase in the percentage of
γH2AX-positive cells, a marker of DSBs formation, and
significant changes in γH2AX staining for both drugs were
attained in U251-MG cells. As expected, TMZ induced a
strong increase in γH2AX-positive nuclei in glioma cells.
As TMZ was more efficient in promoting DNA damage, we
next verified the sensitivity of glioma cell lines to this drug.
Surprisingly, all three cell lines showed a higher resistance to
TMZ than to HDACi used in this study (Figure 4b compared
with Figure 1a). In fact, at the maximal concentration of
500 μM, TMZ did not even reach a 40% decrease in cell
viability of the most sensitive cell line U87-MG compared with
more than 70% attained by HDACi at the highest doses.
To determine the role of caspase activation in HDACi-
induced DNA damage, we next analyzed the effect of caspase
inhibition in γH2AX-positive cells after SAHA treatment
(Figure 4c). Results obtained show that caspase inhibition
with Q-VD-OPh did not block the formation of DSBs in
genomic DNA, indicating that SAHA-induced DNA damage
occurs independently of caspase activation.
It has been reported that HDAC inhibition produces an
increase in reactive oxygen species (ROS) and that this could
contribute to the promotion of DNA damage. We therefore
analyzed ROS production in HDACi-treated cells (Figure 4d).
Both HDACi tested caused a significant increase in ROS
abundance, whereas TMZ did not have this effect. ROS
production correlated with an increased protein carbonylation
in SAHA-treated U87-MG cells (Supplementary Figure 2A).
SAHA-induced ROS generation was blocked by glutathione
(GSH) addition (Figure 4d). The mechanism involved in
SAHA-induced ROS production in tumoral cells has been
proposed to be by the upregulation of thioredoxin-binding-
protein-2 (TBP-2) and by the downregulation of thioredoxin
activity.12We assessed the effect of both HDACi on TBP-2 and
thioredoxin protein levels in our cell model, but we did not
detect any change neither in TBP-2 nor in thioredoxin
expression (Supplementary Figure 2B).
With the aim to determine whether ROS production is
involved in HDACi-induced DNA damage, we checked γH2AX
staining on SAHA- and TMZ-treated cells in the presence or
absence of ROS inhibitors. We observed that ROS scaven-
ging with 15mM NAC partially prevented DNA DSBs forma-
tion in U87-MG cells and in U251-MG cells, but not in LN229
cells (Figure 4e), pointing out to the existence of an additional
molecular alteration that results in DSBs formation in addition
to oxidative stress.
HDACi affect cell cycle progression by decreasing G2
checkpoint kinase expression: Wee1 and Chk1. To further
characterize glioma cell response to SAHA and VPA, we next
analyzed cell cycle distribution by flow cytometry. We
observed that, after 24 h, HDACi promoted a significant
decrease of U87-MG and LN299 cells in S phase and an
increase of cells in G2/M (Figure 5a). Changes on U251-MG
cells reached significance after 48h of incubation (data not
shown). In addition, an increase of cells in G0/G1 phase was
observed in LN229 cells. The reduction of cells in S phase
can be due to the promotion of cell cycle arrest or a faster
progression to the G2/M phase. However, only LN229 cells
showed an arrest in G0/G1. The increase of G2/M-cell
population at the expense of G0/G1 and S phases suggests
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Figure 3 HDACi promote DNA fragmentacion in glioma cell lines, which is dependent on caspase activation. (a) DNA fragmentation analysis on glioma cells treated for 48 h
with 10 μM SAHA combined or not with the pan-caspase inhibitor Q-VD-OPh (5 μM) by PFGE (HMWF, upper picture) and ladder (LMWF, lower picture) procedures. As a positive
control, LN229 cells were treated with 1 μMSTS for 48 h. (b) Analysis of the effect of BCL-X overexpression on DNA fragmentation (HMWFand LMWF) induced by 10 mM VPA or
10 μM SAHA on U251-MG glioma cells. Bcl-xL expression was checked by western blot (upper panel). (c) Downregulation of CAD expression with specific shRNA (4 and 5)
blocks the formation of 50- Kb fragments and low-molecular weight fragmentation on U251-MG cells treated for 48 h with 10 μM SAHA. (d) Western blot of CAD on U251-MG
cells transduced with lentiviral vectors containing CAD shRNA or scrambled sequence (Scr). Equal loading was verified by GAPDH detection of the same membrane (lower
panel). Each DNA integrity assay shown in a, b and c was repeated three times and a representative image is shown. (e) Cell viability analysis by cell counting using trypan blue
exclusion on glioma cells treated with 10 μM SAHA or 5 μM Q-VD-OPh or both combined for 48 h. Bars depict mean±S.E.M. from four independent experiments. Statistical
analysis was performed by the Student's T-test, no significant differences (n.s.) were obtained by comparing SAHA and SAHA+ Q-VD-treated cells
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an alteration on G2 checkpoint. Interestingly, subG1 peak
increased in all glioma cell lines after 48 h of treatment
(Supplementary Figure 3). Therefore, we next checked
whether SAHA induced apoptosis in glioma cells, using
Annexin V-Propidium Iodide (PI) double staining. Data
presented on Figure 4e show that SAHA promoted an
increase in the percentage of Annexin V-positive cells in the
PI-negative population (conserved membrane integrity, left
bar-graph), whereas no significant changes were observed in
the PI-positive cell population, indicating phosphatidylserine
exposure in the cell membrane. These results indicate that
SAHA promotes apoptotic cell death in glioma cells.
The accumulation of cells in G2/M prompted us to check
whether HDACi affect the expression of G2 checkpoint
kinases: Chk1 and Wee1. We observed that 10 μM SAHA
caused a strong decrease in Chk1 and Wee1 protein
abundance (Figure 6a), correlating with a decrease in cdc2
phosphorylation on Tyr-15, which is the final effector for
M-phase progression and Wee1 substrate. VPA treatment
had a weaker effect and also reduced the amount of Chk1
and Wee1 in U87-MG and LN229 cells, respectively. In
contrast, the treatment with TMZ, which directly causes DNA
damage, did not affect the amount of Chk1 and Wee1
kinases. Interestingly, the more resistant cell line U251-MG
Figure 4 HDACi promote DNA damage by DSBs formation in glioma cell lines. (a) Analysis of DNA DSB formation by immunofluorescence of γH2AX-positive nuclei in glioma
cells treated for 48 h with 10 mM VPA, 10 μM SAHA or 100 μM TMZ. Data are mean±S.E.M. from five independent experiments. (b) WST-1 cell viability assay on glioma cell
lines exposed to increasing concentrations of TMZ (from 10 to 500 μM) for 48 h. Data shown are mean± S.E.M. from three independent experiments. (c) Analysis of γH2AX-
positive nuclei on glioma cells treated with 5 μM Q-VD-OPh, 10 μM SAHA or both combined for 48 h. Bars depict mean±S.E.M. from four independent experiments. (d) ROS
production measured by flow cytometry on glioma cells treated with 10 mM VPA, 10 μM SAHA or with 10 μM SAHA in the presence of 10 mM GSH. Data are mean± S.E.M. from
four independent experiments. (e) Analysis of γH2AX-positive nuclei on glioma cells treated with 10 μM SAHA or 100 μM TMZ in the presence or absence of 15 mM N-acetyl-L-
cysteine (NAC). Bars depict mean±S.E.M. from four independent experiments. Statistical analysis was performed by the Student's T-Test, *Po0.05, **Po 0.01, ***Po0.001 in
comparison with NT cells or ##Po0.01 in comparison with SAHA-treated cells
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expresses higher levels of Wee1, followed by LN229 cells
and the U87-MG cells. Chk1 was also more expressed in
U251-MG and LN229 cells than in U87-MG cells. Results
obtained by western blot agreed withWee1 and Chk1 mRNA
levels measured by quantitative real-time RT-PCR
(Figure 6b), indicating that HDACi affect Wee1 and Chk1
expression at the transcriptional level.
As the expression of cdc2 was not affected by HDACi
treatment, but the inhibitory phosphorylation on Tyr-15
diminished, we next checked the expression of its cyclin
partner (Figure 6a). We observed that cyclin B1 decreased
after HDACi treatment and the expression of the cell cycle
inhibitor p21 was strongly increased concurring with published
data.13 In contrast, the amounts of cdc25A, a phosphatase
involved in the regulation of G1/S and G2/M checkpoints,14
were unaffected, suggesting that cells were not arrested
through a decrease in cdc25A. As cdc25A is regulated post-
translationaly and by subcellular localization, a more detailed
characterization of other cell cycle regulators in synchronized
cells would be necessary to confirm whether cell cycle arrest
occurs on a subpopulation.
Wee1 inhibition has been reported to increase replication
stalling and DSBs induced formation by the endonuclease
Mus81.15,16 Therefore, we checked whether Mus81 is
implicated in HDACi-induced DNA damage. As shown in
Figure 6c, none of the drugs altered the expression of Mus81.
Moreover, Mus81 downregulation by shRNA did not reduce
SAHA-induced DSBs formation nor low- and high-molecular
weight DNA fragmentation either (Figures 6d and e), discard-
ing the implication of this endonuclease in SAHA DNA-
damaging effects.
Figure 5 HDACi treatment of glioma cell lines alters cell cycle progression, decreasing the percentage of cells in S phase and increasing cell population in G2/M. (a) Cell
cycle analysis by flow cytometry of glioma cell lines treated for 24 h with 10 mM VPA, 10 μM SAHA or left untreated. Bar graph shows the mean of the percentage of cell in G0/G1,
S and G2/M phases with error bars (S.E.M.) from three independent experiments. Plots on the right are representative results from one experiment. (b) Percentage of apoptotic
cells (Annexin V positive and PI negative) and dead cells (PI positive) after 24 h of treatment. Results are mean± S.E.M. from four independent experiments. Statistical analysis
was performed by the Student's T-test and significance is shown by *Po0.05; **Po0.01
HDACi abrogate G2 checkpoint in glioma cells
M Cornago et al
7
Cell Death and Disease
HDACi cause glioma cell death by promoting mitotic
catastrophe. The fact that HDACi cause a decrease in the
expression levels of Wee1 and Chk1 made us to hypothesize
that cell death may occur through mitotic catastrophe due to
the accumulation of DNA damage that cannot be repaired
before mitosis.17,18 Therefore, we next analyzed by confocal
Figure 6 SAHA and VPA reduce the levels of expression of G2 checkpoint gatekeepers Wee1 and Chk1. (a) Analysis of the effect of HDACi on Wee1 and Chk1 protein
expression and on the phosphorylation status of cdc2 (Tyr-15) in glioma cells. Cell cycle regulators, Cyclin B1, p21 and cdc25A, were also analyzed. Cells were treated for 24 h
with 10 mM VPA, 10 μM SAHA or 100 μM TMZ, and protein extracts were analyzed by electrophoresis and western blot using specific antibodies against proteins indicated on the
left of the panels. Representative blots of three independent experiments are shown. (b) Analysis of Wee1 and Chk1 mRNA after 24 h of HDACi treatment of glioma cell lines by
reverse transcription and quantitative real-time PCR. Bars depict the mean±S.E.M. of four independent experiments. (c) Expression of Mus81 endonuclease in glioma cells
treated as described above by western blot. Equal loading was verified by α-tubulin detection on the same membrane. (d) Downregulation of the endonuclease Mus81 do not
prevent DSBs formation in SAHA-treated U251-MG cells. The efficacy of two specific shRNA against the mRNA of Mus81 (1 and 2) was verified by western blot (upper panel).
Percentage of γH2AX-positive cells after 48 h of incubation in the presence of 10 μM SAHA or 100 μM TMZ of lentivirus-transduced cells. Data are mean± S.E.M. from three
independent experiments. (e) Analysis of DNA fragmentation after Mus81 downregulation with shRNA. Representative gels of three independent experiments are shown, of high-
molecular weight DNA fragmentation (upper panel) and low-molecular weight DNA fragmentation (lower panel) analysis
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microscopy the nuclear morphology of cells in division after
SAHA treatment. Untreated cells had a normal distribution of
chromosomes in metaphase, and mitotic spindles were
correctly formed (Figure 7a). However, on SAHA treatment
dividing cells showed aberrant metaphase morphologies:
chromosomes were not aligned at the metaphase plate,
Survivin was not recruited to centromeres and an abnormal
distribution of mitotic spindle was observed (Figure 7a).
Aberrant mitotic figures were formed, and no cells in
telophase or cytokinesis were observed, indicating that cells
cannot complete mitosis leading to cell death. In addition we
observed that cells enter mitosis with damaged DNA, as
chromosomes from SAHA-treated cells were labeled with the
γH2AX antibody (Figure 7a, right image). In addition, HDACi
promoted a decrease in the amount of Survivin and TPX2
(Figure 7b), indicating a deficit of proteins relevant for correct
Figure 7 HDACi promote cell death by mitotic catastrophe. (a) Analysis of U251-MG cells in metaphase after SAHA treatment by immunofluorescence of Survivin (in green,
left panel) and TPX2 (in green, middle panel), α-tubulin (in red, left and middle panels), γH2AX (in red, right panel) and nuclear staining with Hoescht 33342 (in blue, all panels).
Images were acquired using an Olympus IX-70 confocal microscope and representative pictures from three independent experiments are shown. (b) SAHA and VPA reduce the
expression levels of Rad51, Survivin and TPX2 in glioma cell lines. Total cell lysates from glioma cells were analyzed by electrophoresis and western blot using specific antibodies
against the proteins indicated on the left. Representative blots from three independent experiments are shown. (c) Analysis of the effect of SAHA on Wee1, Chk1, TPX2 and
Survivin protein expression in human GBM primary cultures. Representative blots are shown from three independent experiments. Equal loading was checked by membrane
staining with naphtol blue. (d) Caspase 2 protein and mRNA expression in HDACi-treated glioma cell lines. After a 24-h treatment with 10 mM VPA or 10 μM SAHA, cells were
processed for western blot analysis of Caspase-2 (upper panel) or RNAwas extracted to perform quantitative RT-PCR (lower table). Data are shown as a ratio versus non-treated
cells, and the mean± S.E.M. from three independent experiments is summarized. Statistical analysis were performed by the Student's T-test being *Po0.05; **Po0.01.
(e) Caspase-2 activity assay on U251-MG cells treated for 24 h with 10 mM VPA, 10 μM SAHA in the presence or absence of 5 μM Q-VD-OPh. Cell lysates were incubated with
Ac-VDVAD-AFC fluorogenic substrate up to 8 h and its cleavage was measured hourly using a fluorometer. Bars depict mean±S.E.M. from three independent experiments.
Student's T-test was performed by comparing data from treated versus non-treated (NT) cells (*Po0.05, ***Po 0.001)
HDACi abrogate G2 checkpoint in glioma cells
M Cornago et al
9
Cell Death and Disease
mitosis completion. In addition, we determined the expres-
sion of Rad51, a protein involved in homology-directed repair
of DNA DSBs. Interestingly, HDACi also reduced the
expression levels of Rad51 in glioma cell lines in comparison
with untreated cells and TMZ-treated cells (Figure 7a).
Therefore, this indicates that HDACi impair DNA repair
mechanisms in glioma cells, as it has been described in
other types of tumor cells.19
As HDACi induced a strong decrease of key proteins
involved in cell cycle control and mitosis, we verified whether
these effects were extensive to primary GBM cultures. Cells
isolated from human GBM tumors were treated with 10 μM
SAHA for 24 h (Figure 7c). Three of the four primary GBM
cultures reduced the expression of Wee1, Chk1, Survivin and
TPX2 after SAHA treatment. Only cells of GBM C48, which
expressed very low levels of these proteins in basal condi-
tions, did not show the same response. These results suggest
that HDACi have the same molecular effects on glioma cells
independently of their origin and genetic alterations, and
validate the results obtained in glioma cell lines. Therefore,
HDACi alter the expression of proteins necessary for tumoral
cell proliferation, which have been previously proven to be
involved in gliomagenesis.
Together, these results indicate that glioma cells treated with
SAHA die during mitosis by a mechanism involving mitotic
catastrophe. One of the initial events that have been reported
during this type of cell death is the activation of Caspase-2,
upstream of cytochrome c release.20 Therefore, we checked
Caspase-2 activation after HDACi treatment (Figure 7d). We
observed that HDACi caused a decrease of procaspase-2 (51
kDa) protein, but no cleaved formswere detected (p32 or p18).
However, Caspase 2 mRNA levels were unchanged in
U251-MG and LN229 cells after HDACi treatment (table in
Figure 7d). Measurement of caspase-2 activity in U251-MG
cell lysates confirmed that VPA and SAHA promoted the
activation of caspase 2, and that Q-VD-OPh addition blocked
its activation (Figure 7e). Therefore, our results demonstrate
the implication of Caspase 2 in glioma cell death induced
by HDACi.
Discussion
Our aim was to characterize the molecular changes induced
by broad-range HDAC inhibitors that are used for killing
chemotherapy-resistant glioma cells. Here we have demon-
strated that two structurally different HDACi, SAHA and VPA,
have multiple effects in glioma cancer cells that result in
oxidative stress, DNA damage and the activation of the
apoptotic mitochondrial pathway. However, the HDACi-
induced apoptotic pathway is not the main cause of glioma
cell death. Rather, HDACi treatment impairs G2 checkpoint,
pushes glioma cells to enter mitosis before DNA damage is
repaired and decreases the expression of proteins that have
crucial roles in mitosis, thus triggering cell death by mitotic
catastrophe.
HDAC inhibition in glioma cell lines causes cell death in a
dose-dependent manner, whereas those cells show resis-
tance to the chemotherapeutic agent TMZ. The resistance of
GBM cells to chemo- and radiotherapy has recently been
attributed to the overexpression of the G2 checkpoint kinase
Wee1.18 We have shown that HDAC inhibition alters the
expression of two G2 checkpoint kinases, Wee1 and Chk1,
and results in cells entering mitosis before DNA-damage
repair. In accordance with our results, pharmacologic inhibi-
tion of G2 checkpoint kinases Wee1 and Chk1 has been
shown to have anti-tumoral effects in neuroblastoma cells both
in vitro and in vivo 21 and cause DNA double-strand breaks in
cancer cells in the absence of DNA-damaging chemo-
therapeutic drugs.22 In addition, Wee1 inhibition sensitizes
GBM cells to ionizing radiation and pushes cancer cells onto
mitotic catastrophe.18 In contrast, Chk1 inhibition in combina-
tion with a DNA-damaging drug, gemcitabine, drives rapid
chromosome fragmentation followed by caspase-independent
cell death.17 In fact, Chk1 has been demonstrated to control
mitotic DNA damage checkpoint by delaying mitotic exit of
DNA-damaged cells by regulating mitotic catastrophe.23 The
role of Chk1 downregulation in HDACi-induced cell death has
been previously demonstrated by Brazelle et al.24 in non-small
cell lung cancer cells. Nevertheless here we describe for the
first time the implication of Wee1 kinase in HDACi effects. Our
results demonstrate that G2 checkpoint kinases are molecular
mediators of HDACi-induced cell death on GBM cells and
highlight the relevance of the administration of multitarget
therapies for the treatment of resistant tumors.
Thioredoxin inactivation by the induction of thioredoxin-
binding protein (TBP-2) has been previously reported to be
important for HDACi-induced ROS production and DNA
damage in different cancer cell types.10,25,26 However, we
have not detected changes in TBP-2 expression, thus
discarding this mechanism in our model. In fact, ROS
production was implicated in DNA damage observed in U87-
MG and U251-MG cells, but not in LN229, indicating that other
molecular alterations may participate, such as alteration of the
DNA-repair machinery,19 the acetylation of histones involved
in DNA repair such as Histone 427 or histone 328 and the
decrease in G2 checkpoint kinases.22 Our results show that
HDACi display at least two of these effects on glioma cells, as
they decrease the expression of G2 checkpoint kinasesWee1
and Chk1 and DNA damage repair protein Rad51. As the
endonuclease Mus81 has been implicated in the DNA
damage response induced by Wee1 depletion16 and in
Chk1-deficient cells,29 we also checked whether Mus81 was
amediator of DSB formation andDNA fragmentation in SAHA-
treated cells. However, our results indicate that Mus81 does
not participate in the DNA-damaging effects of SAHA.
HDACi are able to activate the mitochondrial caspase-
dependent apoptosis pathway in glioma cells. However, our
results indicate that this event does not determine glioma cell
death, as caspase inhibition does not prevent it. The detailed
analysis of cell cycle distribution and nuclear morphology
rather indicates that HDACi promote cell death by mitotic
catastrophe due to an aberrant mitotic spindle formation, and
the detection of caspase-2 activation supports this conclusion.
In accordance with our results, a previous work described that
HDACi treatment temporarily delays mitotic progression
affecting prometaphase due to activation of the spindle
assembly checkpoint, involving aberrant chromosome segre-
gation and failed cytokinesis.30 Similarly, Trichostatin A has
been shown to induce a delay at the G2/M transition,
chromosome missegregation and multi-nucleation, and
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thereby it leads to cell death by promoting exit from aberrant
mitosis without spindle checkpoint.31 Our results provide an
explanation to these observations, as they show that HDACi
significantly reduce the expression of G2 gatekeepers Wee1
and Chk1, in addition to other proteins involved in chromo-
some segregation, DNA repair and mitotic spindle formation.
Therefore, HDACi-treated glioma cells die by a mechanism of
mitotic catastrophe involving the activation of caspase-2 and
the mitochondrial pathway due to DNA-damage accumulation
and G2 checkpoint impairment, according to the current
concept of mitotic catastrophe.32
Our results show that the expression of Rad51, a protein
involved in DNA repair by homologous recombination, is
reduced in HDACi-treated glioma cells. The same effect was
described for the HDACi PCI-24781.33 In fact, it has been
reported that SAHA affects the expression of proteins involved
in several mechanisms of DNA repair: homologous recombi-
nation, non-homologous end joining or base excision repair19
in different kinds of tumor cells, such as RAD50 and MRE11 in
prostate and lung cancer cells,10 Ku70, Ku80 and RAD50 in
melanoma cells34 and Rad51 and BRCA1 in prostate cancer
cells.35 HDACi-induced impairment of the DNA repairing
potential could explain why antioxidant treatment does not
prevent DSB formation in LN229 glioma cells. This implies that
HDACi effects on proteins involved in DNA-repair are common
and can contribute importantly to DNA damage, in conjunction
with ROS production.
Our results also show that Survivin, an antiapoptotic protein
that has been shown to be important for the regulation of
mitosis,36 is downregulated by HDACi treatment in glioma
cells. Survivin is overexpressed in most cancers and it can be
used as a prognostic factor for several kinds of tumors.37
Therefore, therapies designed to downregulate or block
Survivin have been experimentally tested. A dominant-
negative mutant of Survivin significantly induced mitotic
catastrophe and apoptosis, and inhibited tumor growth in a
colon cancer xenograft model.38 It has also been described
that cell division in the absence of Survivin results in defects in
chromosome alignment, failure of cytokinesis and eventually
cell death.39 Recently, it has been shown that the disruption of
the Survivin-Ran complex by a pharmacological inhibitor
abolishes survival and growth of glioma stem cells.40 There-
fore, our findings together with previous data point out to the
relevance of Survivin in cancer cell proliferation and support
the role of this protein as a mediator of HDACi-induced mitotic
catastrophe in glioma cells.
In conclusion, our results show that SAHA and VPA, which
are more efficient than the chemotherapeutic drug TMZ in
killing glioma cells, reduce the expression of proteins involved
in processes relevant for tumor growth and survival: G2/M
checkpoint gatekeepers, DNA repair mechanisms and pro-
teins involved in mitotic spindle formation and chromosome
segregation duringmitosis, thus leading to cell death bymitotic
catastrophe. These findings support the view that drugs
targetingmultiple processes are more efficient in killing cancer
cells than DNA-damaging agents.
Materials and Methods
Materials and cell culture. Cell culture media, supplements and sera were
from Gibco Life Technologies (Carlsbad, CA, USA). Temozolomide (3,4-dihydro-3-
methyl-4-oxoimidazo-[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, TMZ), valproic acid
(VPA), SAHA (suberanilohydroxamic acid, vorinostat), L- reduced glutathione (GSH)
and N-acetyl-L-cysteine (NAC) were purchased from Sigma-Aldrich (St. Louis, MO,
USA). The TNF-related apoptosis-inducing ligand (TRAIL) was acquired from
BioTrend Chemikalien GmbH (Köln, Cologne, Germany). Q-VD-OPh was purchased
from Calbiochem (Merck KGaA, Darmstadt, Germany).
Glioma cell lines: U87-MG and U251-MG cells were obtained from CLS Cell
Lines Service (Eppelheim, Germany), and LN229 cell line was from ATCC
(Manassas, VA, USA). Cells were maintained in culture as indicated by the supplier
at 37 °C and 5% CO2 atmosphere and were subcultured by trypsinization twice
a week.
Primary cultures: Tumor biopsies were obtained from Hospital Universitari
Arnau de Vilanova (HUAV; Lleida) and processed following the procedure described
by Dr Seoane group.41
Lentiviral Construction and Transduction. Human BCL-X cDNA was
cloned into the expression lentiviral vector pEIGW.42 Primers for small hairpin RNA
interference (shRNA) and control plasmid DNA pLKO.1-puro-SHC002 were bought
to Sigma (hMus81-1: TRCN00000049727; hMus81-2: TRCN00000290878). Human
CAD shRNA were kindly provided by Dr. Victor Yuste (UAB, Barcelona).43 Viruses
were prepared and titered as described in Bahi et al.44 Cells were usually treated
after 2–3 days of viral transduction when expression vectors were used or after
4–5 days when shRNA experiments were performed.
WST-1 viability assay. Cell viability was measured using a colorimetric assay
with WST-1 reagent (Roche Diagnostics GmbH, Mannheim, Germany). Glioma cells
were seeded in 96-well plates (2–4 × 103 cells/well), and, after 24 h, cells were
treated for 48 h as indicated in the figures. WST-1 reagent was added and
absorbance at 450 nm and 600 nm was measured in a BioTek plate reader (BioTek
Instruments, Winooski, VT, USA) every hour up to 3 h. Cell viability was calculated
as percentage of absorbance readings of treated versus untreated cultures.
Clonogenic assay. Cells were plated in six-well plates at a density of 3.5–
7 × 105 cells/well. Once cells reached 70% confluency, HDACi were added and
incubated for 48 h. Afterward, cells were trypsinized, counted by trypan blue
exclusion and re-plated (500 cells/well) in duplicate in six-well plates. Cells were
grown at 37 °C and 5% CO2 in normal medium and left to form colonies for 10 days,
with a mid-term medium replacement. At the end, cells were fixed with cold-
methanol for 10 min and stained with 0.5% crystal violet solution (Sigma) for 10 min
at room temperature. Plates were rinsed carefully in water and left to dry overnight
at room temperature. Finally, plates were scanned and clones were counted.
Flow cytometry
Cell cycle analysis: Cells were seeded in 60-mm petri dishes at 1.25–2.5 × 106
cells/dish, left to adhere and treated as indicated for 24 h. Afterward, cells were
trypsinized and washed in ice-cold PBS, fixed in 70% ethanol and stored at –20 °C
until analysis. Fixed cells were suspended in 500 μl propidium iodide (PI)/ RNase
staining buffer (Becton Dickinson, Franklin Lakes, NJ, USA), incubated for 30 min at
37 °C and analyzed in a BD FACSCanto II cytometer (Becton Dickinson). Data
analysis was performed using ModFit LT software (Verity software house, Topsham,
ME, USA).
Measure of ROS: Cells were plated in 35-mm dishes at 3.5 or 7 × 105 cells/dish,
left to adhere for 1 day and treated with the indicated drugs for 24 h at 37 ºC and 5%
CO2. At the end Cell Rox Green Reagent (Life Technologies) was added to a final
concentration of 2.5μM and incubated for 30 min at 37 ºC. Cells were washed twice
in cold PBS, trypsinized and suspended in 1ml PBS. Cells were analyzed in a BD
FACSCanto II cytometer (Becton Dickinson).
Annexin V and propidium iodide staining: After 24 h of treatment with
10 μM SAHA, cells were collected and incubated with 1 μg/ml Annexin V-FITC
(ENZO Life Sciences, Farmingdale, NY, USA) and 2.5 μg/ml PI (BD Transduction
Laboratories, Becton Dickinson, Franklin Lakes, NJ, USA) in 200 μl buffer
containing 10 mM Hepes/KOH (pH 7.4), 140 mM NaCl and 2.5 mM CaCl2 for 30 min
at room temperature, and the cells were analyzed using a BD FACSCanto II
cytometer (Becton Dickinson).
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Western blot and Immunofluorescence. Antibodies were obtained from
commercial sources: Chk-1, MGMT, CAD, g-Histone-2-AX (gH2AX), Ki-67, and
fodrin from Millipore (Billerica, MA, USA); Wee1, Caspase-3 and Caspase-9 from
Cell Signaling Technology (Danvers, MA, USA); α-tubulin from Sigma; Cdk1, Cdk1-
PY15, GAPDH and Cyclin B1 from Abcam (Cambridge, UK); Mus81 from Thermo
Scientific (Waltham, MA, USA); Survivin, TPX2, Rad51 from Novus Biologicals
(Cambridge, UK); p21 and cdc25A from Santa Cruz Biotechnology (Dallas, TX,
USA). Protein cell extracts and western blot was performed as previously
described.44 Blots were developed using the enhanced chemiluminescence (ECL)
or Super Signal reagents (Thermo Scientific). Membranes were reprobed with anti-
α-tubulin or anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibodies,
or stained with napthol blue black dye (Sigma) for loading control.
For immunofluorescence experiments, glioma cells were grown on glass
coverslips of 12 mm diameter and treated as described. Cells were fixed with 4%
paraformaldehyde in PBS for 20 min at room temperature, blocked in 5% bovine
serum albumin (BSA), 5% fetal bovine serum, 0.1% Triton X-100 in PBS for 1h and
incubated for 1h at RT or overnight at 4 °C with primary antibodies. Samples were
then incubated with secondary antibodies for 1h , stained with Hoechst 33342
(Molecular Probes Life Technologies) and mounted using Vectashield (Vector
Laboratories, Peterborough, UK) or Mowiol (Sigma) mounting medium. Secondary
antibodies used were anti-rabbit IgG-Alexa Fluor 488 and anti-mouse IgG-Alexa Fluor
594 (Molecular Probes Life Technologies).
Quantitative RT-PCR. Total RNA was isolated from glioma cell lines after 24 h
of treatment using the RNeasy kit Qiagen (Hilden, Germany) and quantified in a
Nanodrop spectrophotometer (Wilmington, USA). Quantitative RT-PCR was
performed using TaqMan Gene expression assays (Chk1, Wee1, Caspase 2 and
GAPDH) and TaqMan Gene expression Master Mix (Life technologies) as previously
described.45
DNA integrity assay. Aliquots of treated and non-treated cells were collected
by cell scraping, and pellets were frozen at –80 ºC. DNA integrity was checked by
pulse-field gel electrophoresis (PFGE) and low-molecular weight fragmentation by
agarose gel electrophoresis following a previously described procedure.44
Caspase activity assays. Caspase activity was measured as previously
described.46 Cells were treated with 10 mM VPA or 10 μM SAHA for 24 h, in the
presence or absence of 5 μM Q-VD-OPh. Cells were lysed in a buffer containing
20 mM HEPES/NaOH (pH 7,2), 5 mM MgCl2, 1%PMSF, 1% Triton, 5 mM EDTA and
10 mM DTT, and protein concentration in the lysates was measured by the DC
Protein assay (BioRad, Hercules, CA, USA). Equal loads of protein were added in
96-well plates and mixed with 50 mM of fluorogenic substrates: Ac-DEVD-AFC
(Millipore, Billerica, MA, USA) for Caspase-3-like activity or Ac-VDVAD-AFC (ENZO
Life Sciences, Farmingdale, NY, USA) for Caspase-2 activity, both at a final
concentration of 50 μM in 96-well plates. Assay plates were incubated at 37 °C, and
fluorescence was read at intervals of 1 h during the next 8 h in a BioTek FL 600
fluorimeter (BioTek Instruments,), with excitation filter set at 360 nm or 400 nm and
emission filter at 530 nm or 505 nm for Caspase-3 or Caspase-2, respectively. Data
obtained for different experimental conditions were compared within the linear
phase of absorbance increase. Data are mean of four independent experiments.
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